David Pompliano is a drug discovery entrepreneur. Working with venture-capitalists and academicians, he focuses on creating scientifically precocious, game-changing new commercial enterprises based on cutting edge science and technology discovered in academia.

David is an Operating Partner of Accelerator Life Science Partners.  With Accelerator LSP and Gates Foundation backing, David co-founded Lodo Therapeutics in 2015 with Professor Sean Brady (Rockefeller University), and served as its Chief Scientific Officer (CSO) until September 2018. Lodo Therapeutics is a New York City-based company focused on metagenomics-based discovery and synthetic biological manipulation of novel secondary metabolite biosynthetic pathways to produce new medicines.  David continues to work with Accelerator to ideate and build new biotechnology companies.

David has over 25 years of experience in the biopharmaceutical industry. Prior to Lodo Therapeutics, he served as CSO of Revolution Medicines, a drug discovery company he co-founded while an Entrepreneur-in-Residence at Third Rock Ventures. Before that, he was CEO of BioLeap, a platform technology-based biopharma company. Earlier, he served as a senior pharmaceutical executive at GlaxoSmithKline and Merck, where he led drug discovery teams that produced pre-clinical credentials for >30 development candidates and four registered anti-infective (Altabax) and oncology (Tykerb, Votrient, Promacta) drugs.

As Principal and Owner at Sanderling Consulting LLC, David participates in many anti-infective discovery review meetings and serves on the scientific advisory boards of several biotechnology companies, government agencies and philanthropic organizations.

David has published more than 50 peer-reviewed papers in the areas of infectious diseases, cancer drug discovery and mechanistic enzymology, and has presented at over 50 international lectures.

He earned his BSc and PhD degrees in chemistry from the University of Virginia and Stanford University, respectively. He conducted research in enzymology and molecular biology as a National Institutes of Health Postdoctoral Fellow in Jeremy Knowles’ laboratory at Harvard University.

Contact David: